Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning by Bushnell, Greta A. et al.
Dosing of selective serotonin reuptake inhibitors in children and 
adults before and after the FDA black-box warning
Greta A Bushnell, MSPH1, Til Stürmer, MD, MPH, PhD1, Sonja A Swanson, ScD2,4, Alice 
White, MSPH, PhD1, Deborah Azrael, PhD3, Virginia Pate, MS1, and Matthew Miller, MD, 
MPH, ScD5
1Department of Epidemiology at the University of North Carolina at Chapel Hill Gillings School of 
Global Public Health, Chapel Hill, NC 2Department of Epidemiology at Harvard University, 
Harvard T. H. Chan School of Public Health, Boston, MA 3Department of Health Policy and 
Management at Harvard University, Harvard T. H. Chan School of Public Health, Boston, MA 
4Department of Epidemiology, Erasmus MC, Rotterdam, Netherlands 5Department of Health 
Science at Northeastern University Bouvé College of Health Sciences, Boston, MA
Abstract
Objective—Prior research evaluated various effects of the antidepressant black-box warning on 
the risk of suicidality in children, but the dosing of antidepressants has not been considered. This 
study estimated, relative to the FDA warnings, whether the initial antidepressant dose prescribed 
decreased and the proportion augmenting dose on the second fill increased.
Method—The study utilized the LifeLink Health Plan Claims Database. The study cohort 
consisted of commercially insured children (5–17 years), young adults (18–24 years), and adults 
(25–64 years) initiating an SSRI (citalopram, fluoxetine, paroxetine, or sertraline) from 1/1/2000 
to 12/31/2009. Dose-per-day was determined by days supply, strength, and quantity dispensed. 
Initiation on low dose, defined based on guidelines, and dose augmentations (dose increase >1mg/
day) on the second prescription were considered across time periods related to the antidepressant 
warnings.
Results—Of 51,948 children who initiated an SSRI, 15% initiated on low dose in the period 
before the 2004 black-box warning and 31% in the period after the warning (a 16 percentage-point 
change); there was a smaller percentage-point change in young adults (6%) and adults (3%). The 
overall increase in dose augmentations in children and young adults was driven by the increase in 
patients initiating on a low dose.
Conclusions—As guidelines recommend children initiate antidepressant treatment on low dose, 
findings that an increased proportion of commercially insured children initiated an SSRI on low 
dose after the 2004 black-box warning suggest prescribing practices surrounding SSRI dosing 
improved in children following the warning but dosing practices still fall short of guidelines.
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Introduction
In June 2003, the U.S. Food and Drug Administration (FDA) released a public health 
advisory recommending that children treated for major depressive disorder (MDD) should 
not be given paroxetine because it might increase suicidal thoughts and behaviors (1). In 
October 2004, the FDA added a black-box warning to all antidepressants(2) based on an 
FDA sponsored meta-analysis that found children randomized to antidepressants had twice 
the rate of suicidal ideation and behavior compared with children randomized to placebo (3, 
4). Based on additional analyses, the black-box warning was expanded in May 2007 to 
include patients ages 18–24 years (5). The warnings included recommendations for close 
patient monitoring after antidepressant initiation (2).
Following the black-box warning, antidepressant use overall decreased in youth,(6–16) 
paroxetine use decreased,(7, 11, 14) and fluoxetine use increased (11, 15). Other studies 
have documented shifted care from generalists to psychiatric specialists,(6, 8, 17) and a 
decrease in new pediatric depression diagnoses (9, 10). Recommendations for improved 
patient monitoring did not lead to significant changes in visit frequency after antidepressant 
initiation(11, 18), although physicians reported increased patient contact with antidepressant 
initiators after the warnings (8, 17).
In 2007, the American Academy of Child and Adolescent Psychiatry (AACAP) practice 
parameters stated that children and adolescents with depressive disorders should initiate 
antidepressant treatment on a low dose (19). Prescribing guidelines from non-US countries, 
published as early as 2005, also suggest initiating selective serotonin reuptake inhibitors 
(SSRI) in children (20, 21), as well as adults (22, 23), at low doses with gradual dose 
titration as evidence suggests antidepressant side effects may be dose related (24–26). 
Higher initial antidepressant dose may be associated with an increased risk of self-harm in 
children and young adults (10–24 years)(27, 28) highlighting the potential importance of 
initiating therapy at lower doses, especially among children and young adults. Despite these 
recommendations, it is uncertain whether starting lower and slowly titrating upward has 
become a more frequent antidepressant treatment strategy, and if so, whether changes in 
prescribing practices have been more pronounced among children than adults.
To our knowledge the only published assessment of whether the black box warnings affected 
prescriber management of antidepressants through dose alterations was a survey of 
practicing pediatricians in Canada, 11% of whom reported that the black-box warning 
affected their management of depression through medication dosing (29). The current study 
examines directly whether, in relation to FDA actions, US prescribers may have begun to 
exert extra caution that influenced initial dosing and subsequent dose titration, especially 
among children and young adults. We do so by assessing if the initial SSRI dose-per-day 
prescribed decreased relative to the FDA black-box warnings, and also whether the 
proportion of children and young adults augmenting SSRI dose on the second fill increased.
Bushnell et al. Page 2
Psychiatr Serv. Author manuscript; available in PMC 2017 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Methods
Datasource & Study Population
We used the LifeLink Health Plan Claims Database, purchased from IMS Health, which 
contains data from over 98 health plans throughout the US. The database includes 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
inpatient and outpatient diagnoses, Current Procedural Terminology, 4th edition (CPT-4) and 
Healthcare Common Procedure Coding System (HCPCS) procedure codes, and records for 
reimbursed, dispensed retail and mail order prescriptions. Records of dispensed prescriptions 
include the National Drug Code (NDC), quantity, days supply, and date of dispensing. The 
study was exempted from the University of North Carolina Institutional Review Board.
The study population consisted of commercially insured individuals initiating SSRI 
treatment between January 1, 2000 and December 31, 2009. Children (5–17 years), young 
adults (18–24 years), and, for comparison, adults (25 to 64 years) were included. SSRIs 
were limited to citalopram, fluoxetine, paroxetine, and sertraline; escitalopram was 
excluded, as it was not FDA approved until late 2002, and therefore no reference of dosing 
before the warnings was available. Eligibility criteria further included: at least a year of 
insurance coverage prior to SSRI initiation; no record of antidepressant use in the prior year; 
6 months of insurance coverage following the initial prescription to help ensure capture of a 
second prescription; and a valid initial dose-per-day as defined subsequently.
Dose-per-day & Dose augmentations
For each SSRI prescription, dose-per-day was calculated based on the days supply, strength 
(from NDC code), and quantity dispensed (11,704 patients were excluded due to missing 
values; 2.2% of the study population). We excluded 3,151 patients (0.6%) with amount-per-
day values (quantity dispensed divided by days supply) outside of 0.5 to 4.0 pills-per-day for 
SSRIs dispensed in tablet form and outside 0.25ml to 20ml for solution form or initial dose-
per-day values <2.5mg/d or values 1.5 times the recommended maximum therapeutic dose-
per-day (citalopram >60mg/d, fluoxetine >120mg/d, paroxetine controlled release (CR) 
>93.75mg/d, paroxetine immediate release (IR) >90mg/d, and sertraline >300mg/d).
We defined low dose by age group and SSRI agent based on available guidelines and 
product labels (22, 23, 30–38): 5–12 years (<10mg/d citalopram, fluoxetine, and paroxetine 
IR and <25mg/d sertraline), 13–17 years (<20mg/d citalopram and fluoxetine, <10mg/d 
paroxetine IR, and <50mg/d sertraline), and 18–64 years (<20mg/d citalopram, fluoxetine, 
and paroxetine IR, <25mg/d paroxetine CR, and <50mg/d sertraline). Paroxetine CR was 
unavailable <12.5mg/d for children 5–17 years. As paroxetine was the only agent in which 
the low dose value for children 13–17 years differed from young adults, we conducted a 
sensitivity analysis using an alternative definition for low dose paroxetine (IR: <20mg/d, 
CR: <25mg/d) in children 13–17 years.
Dose augmentation was defined as an increase of >1mg/d between the initial dose-per-day 
and the dose-per-day of the second prescription. To be eligible for a dose augmentation, 
patients had to fill a second prescription for the same agent within the initial prescription’s 
days supply plus a 30-day grace period. One-percent (n=5,625) of the study population filled 
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two prescriptions of the same SSRI at treatment initiation; we assumed the two prescriptions 
were taken sequentially as the median days supply for patients with two different doses, was 
7 days (interquartile range: 7, 15) for the lower dose and 30 days (30, 30) for the higher 
dose. Therefore, if the dose-per-day values at index differed, the lower dose was considered 
the initial dose-per-day and the higher dose the dose of the second prescription.
Time Periods
Patients were stratified by date of antidepressant initiation into time periods related to three 
historically relevant dates (Appendix figure 1). Period 1, before heightened concerns, 
included the time from 1/1/2000 to 6/18/2003. Period 1 was further divided into two time 
periods (1/1/2000–12/31/2001 and 1/1/2002–6/18/2003) to determine if dosing was stable in 
the years preceding heightened concerns. Period 2 began on 6/19/2003 when the FDA 
recommended that paroxetine not be used in children for the treatment of MDD. Period 3 
began on 10/15/2004 when the black-box warning for children <18 years was announced. 
Period 4 began on 5/2/2007 when the black-box warning was expanded to ages 18–24 years, 
and went until study end (12/31/2009). Primary comparisons considered initiation before 
(1/1/2000–10/14/2004) versus after the 2004 FDA black-box warning (10/15/2004–
12/31/2009). For young adults an additional comparison was considered for before 
(1/1/2000–5/1/2007) versus after the black-box expansion (2/2/2007–12/31/2009).
Covariates
Baseline patient covariates were collected in the year prior to treatment initiation. Covariates 
of primary interest included age at treatment initiation, index antidepressant agent, provider 
specialty, and depression diagnosis. Age categories within children (5–9, 10–12, 13–17) 
were created based on potential variation in dosing and prescribing practices. Provider 
specialty was the specialty associated with the index antidepressant prescription; specialties 
of interest were psychiatry, psychology, and general practice (pediatrics, family practice, and 
general practice). The remaining specialties were classified as other or unknown if missing. 
A depression diagnosis was defined as an inpatient or outpatient diagnostic code (ICD-9-CM 
code 296.2x, 296.3x, 298.0x, 300.4x, 309.0x, 309.1x, 311.xx, 293.83, 296.90, 309.28) in the 
prior year. Additional covariates describe the study cohort (Table 1, footnote).
Analysis
We estimated the proportion of patients initiating on low dose before and after the 2004 
FDA black-box warning and the percentage-point change with the associated Wald 95% 
confidence interval (CI). Results were evaluated by period of initiation and age group and 
were further stratified by SSRI agent to assess whether variation in prescribing practices 
around dosing was apparent by agent (paroxetine was associated with the initial heightened 
warnings and fluoxetine was the only FDA approved SSRI for treatment of MDD in children 
(1, 4)). Results were also stratified by presence of a depression diagnosis in the year prior to 
SSRI initiation and by prescribing provider type. Provider specialty stratification was 
restricted to psychiatry vs. general practice as we cannot be certain of the psychology 
provider makeup given prescribing rights for psychologists were limited to two states during 
the study period. Two sensitivity analyses were conducted: one assumed that the 1% of 
patients who filled two antidepressant prescriptions at initiation took the prescriptions 
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concurrently rather than sequentially (ex. 10+30=40mg vs. 10mg); the other included the 
0.6% of patients who were excluded from primary analyses due to initial dose values that 
were thought to be entry error. Analyses were conducted in SAS version 9.3 (Cary, NC).
Results
Between 2000 and 2009, 51,948 children, 51,653 young adults, and 395,550 adults initiated 
an SSRI. The majority of children initiated sertraline (38%) or fluoxetine (35%) compared 
to citalopram (15%) or paroxetine (11%). A psychiatrist wrote the initial prescription for 
21% of children, 10% of young adults, and 5% of adults (Table 1). Half of children, 45% of 
young adults, and 33% of adults had a depression diagnosis in the year prior to SSRI 
initiation and 29% of children, 28% of young adults, and 22% of adults had an anxiety 
diagnosis.
Initial dose-per-day
Overall, 25% of children 5–9 years, 10% of children 10–12 years, 31% of children 13–17 
years, 21% of young adults, and 19% of adults initiated an SSRI on a low dose. The 
proportion of patients initiating SSRI treatment on a low dose increased over time (Figure 
1). Increases for children 10–12 and 13–17 years began in period 2, the period immediately 
following the initial paroxetine warning, and continued thereafter. The proportion of the 
youngest children (5–9 years), young adults, and adults initiating on low dose increased 
slightly during the initial period; for young adults and adults this stabilized in period 3 and 
further increased only in young adults after the 2007 black-box expansion.
The increase in the proportion initiating on a low dose after the black-box warning compared 
with prior to the black-box warning was most prominent in children 13–17 years (37% vs. 
17%), a relative increase of 116% (Table 2). Results were essentially unchanged in the 
sensitivity analysis that assumed patients with two index antidepressant prescriptions took 
them concurrently and in the analysis that included patients with initial dose values that were 
thought to be from entry error.
The percentage-point change in the proportion initiating on a low dose after the 2004 black-
box warning compared with before was more pronounced among those with a depression 
diagnosis across all age groups: children (18% vs. 14%), young adults (7% vs. 5%), and 
adults (4% vs. 2%), (Table 2). For children the percentage-point change was higher in those 
with a service provider from psychiatry (18%), compared with a provider from a general 
practice (14%).
Among children 13–17 years, the proportion initiating on a low dose differed across agents, 
ranging from 2% among paroxetine initiators to 47% among fluoxetine initiators, with much 
less variation by agent seen in children 5–12 years (13–19%). However, in the sensitivity 
analysis for children 13–17 years, with an alternative low dose definition for paroxetine (IR: 
<20mg/d, CR: <25mg/d), 39% initiated on a low paroxetine dose before the 2004 warning 
and 52% after the warning. Considering all agents for children 13–17 years with the 
alternative paroxetine low dose definition, the percentage-point change was 15% (95% CI: 
14–16): 25% before the warning to 40% after.
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Dose augmentation
Overall, 74% of children (range across four periods: 73–74%), 63% of young adults (range: 
62–65%), and 65% of adults (range: 64–69%) filled a second SSRI prescription for the same 
agent. Of those with a second prescription, 20% of children 5–9 years (980/4,972), 21% of 
children 10–12 years (1,530/7,158), 25% of children 13–17 years (6,538/26,190), 21% of 
young adults (6,809/32,431), and 13% of adults (33,262/258,211) augmented dose. Patients 
initiating on a low dose were more likely to subsequently augment dose compared to non-
low dose initiators (Figure 2). Stratified by initial dose, the proportion of patients 
augmenting dose on the second fill remained stable across the four time periods (Figure 2).
Discussion
Overall, we saw an increase in the proportion of children and young adults initiating an 
SSRI on a low dose in the period after the 2004 black-box warning, compared with the 
period before the warning, with minimal changes in adults. The change in prescribing 
practices surrounding dosing was not universal, as the majority of children were not initiated 
on a low dose by study end. The black-box warning did not mention dosing, however, and 
warnings with specific reference to dosing might have a larger impact on dose-related 
prescribing practices. The increased proportion of children and young adults augmenting 
dose on the second fill after the 2004 warning was accounted for by the increase in low dose 
initiators.
The largest increase in the proportion initiating on a low dose after the 2004 black-box 
warning occurred among children 13–17 years. This may be a result of increased concern 
about suicidal outcomes among this age group relative to younger children, as intentional 
self-harm is more common in this age group (39, 40). Our finding that a lower proportion of 
children 10–12 years, compared with other child age groups, initiated treatment on a low 
dose (10% vs. 25–31%) is likely due to our definition of low dose for citalopram, fluoxetine, 
and sertraline changing for children when they turn 13 (i.e., higher doses constituted ‘low 
dose’). The oldest children in the group aged 5–12 years are more likely to initiate on a dose 
that would be considered low dose for children aged 13–17 years, but considered a non-low 
dose for children 5–12 years.
The change in the proportion of children initiating treatment on a low dose was slightly 
more pronounced for children prescribed antidepressants by psychiatrists compared to those 
prescribed by general practitioners, which may be a result of differential familiarity with 
treatment guidelines, the black-box warnings, or SSRIs themselves. Our finding that the 
proportion initiating on a low dose varies by SSRI agent may in part be due to the definition 
of low dose we used in primary analyses, but may also be related to variation in drug 
formulations that make it harder to prescribe lower doses, e.g., paroxetine CR is not 
available in <12.5mg/d. Given the availability of paroxetine IR and other SSRIs, low doses 
of other SSRIs could have been prescribed if desired.
The official announcement on the decision to add the black-box warning to all 
antidepressants was made more than one year after the FDA issued their initial warning on 
the possible increased suicidality risk with paroxetine. The interval between the initial 
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warning (June 2003) and the formal black box warning (October 2004) was marked by 
media coverage on the risk of suicidality associated with pediatric antidepressant use (41). 
Consistent with prior research that describes decreases in antidepressant prescribing 
beginning before the 2004 warning (6, 7, 11, 14, 15), we observed a change in prescribing 
practices during this time. The change was most pronounced in children 13–17 years, where 
the proportion of patients initiating on low dose was stable during period 1 and then doubled 
after the paroxetine warning.
The black-box warning did not expand to patients 18–24 years of age until 2007. The 
proportion of patients 18–24 years initiating on a low dose stabilized when the 2004 black-
box warning for children (<18 years) was released but increased after the warning was 
expanded to patients 18–24 years. The changes we observed in the proportion of patients 
initiating on low dose therapy in period 2 suggest that the initial warnings for children might 
have influenced prescribing among the 18–24 year old age group. In adults (25–64 years) as 
well, to whom neither black-box warning pertained, there was a similar increase in the 
proportion initiating on a low dose in period 2. These findings of increases after the 
paroxetine warnings may be consistent with spillover effects that have been observed 
previously (42). For example, following a 2005 black-box warning regarding the risk of 
atypical antipsychotic use among elderly patients with dementia, modest decreases in use 
were also seen among those without dementia (43). Comparatively, substantial decreases in 
antidepressant prescribing among children related to FDA communications (6, 7, 10, 14, 15, 
18, 44, 45) were accompanied by modest decreases among adults (6, 14).
Limitations of our study should be considered. The population of antidepressant initiators 
increased across the study, which is a function of the datasource increasing in size; 
consequently, proportions are weighted towards the end of each period. Dose values were 
dependent on correct data entry in dispensed prescription records and free samples may have 
been provided to the patient at treatment initiation, possibly resulting in misclassification of 
the initial dose. We would not, however, expect these sources of misclassification to 
differentially affect children and adults across the time periods. Results are limited to 
patients with continuous insurance enrollment who initiated citalopram, fluoxetine, 
paroxetine, or sertraline and had a non-missing dose. Lastly, the working definition we 
adopted for initiation on a low dose was based on available product labels and guidelines, 
and did not account for treatment indications or patient weight.
Conclusions
Results from this descriptive study indicate that the proportion of children initiating on a low 
dose increased after the 2004 FDA warning on the risk of suicidality in children. The 
increase in children starting on a low dose was apparent after the initial advisory in 2003. 
Given recent findings that the dose of the antidepressant may be associated with an 
increased risk of self-harm,(27, 28) as well as AACAP guidelines indicating that children 
and adolescents with depressive disorders should initiate antidepressant treatment on a low 
dose,(19) our results suggest prescribing practices surrounding SSRI dosing improved in 
children following the black-box warnings but dosing practices still fall short of guidelines.
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Figure 1. 
Proportion of children, young adults, and adults initiating SSRI treatment on a low dose
BBW = Black-box warning
Low dose = 5–12 years (<10mg/d citalopram, fluoxetine, and paroxetine immediate release 
and <25mg/d sertraline); 13–17 years (<20mg/d citalopram and fluoxetine, <10mg/d 
paroxetine immediate release, and <50mg/d sertraline); 18–64 years (<20mg/d citalopram, 
fluoxetine, and paroxetine immediate release, <25mg/d paroxetine controlled release, and 
<50mg/d sertraline); Children 5–17 years: paroxetine controlled release unavailable 
<12.5mg/d
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Figure 2. 
Proportion of children, young adults, and adults augmenting SSRI dose on the second fill
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alo
pra
m,
 fl
uo
xe
tin
e,
 a
nd
 p
ar
ox
et
in
e 
im
m
ed
ia
te
 re
le
as
e 
an
d 
<2
5m
g/
d 
se
rtr
al
in
e),
 13
–1
7 y
ea
rs 
(<
20
mg
/d 
cit
alo
pra
m 
an
d f
luo
xe
tin
e,
 <
10
m
g/
d 
pa
ro
xe
tin
e 
im
m
ed
ia
te
 
re
le
as
e,
 a
nd
 <
50
m
g/
d 
se
rtr
al
in
e),
 18
–6
4 y
ea
rs 
(<
20
mg
/d 
cit
alo
pra
m,
 fl
uo
xe
tin
e,
 a
nd
 p
ar
ox
et
in
e 
im
m
ed
ia
te
 re
le
as
e,
 <
25
m
g/
d 
pa
ro
xe
tin
e 
co
nt
ro
lle
d 
re
le
as
e,
 a
nd
 <
50
m
g/
d 
se
rtr
al
in
e);
 C
hil
dre
n 5
–1
7 y
ea
rs:
 
pa
ro
xe
tin
e 
co
nt
ro
lle
d 
re
le
as
e 
un
av
ai
la
bl
e 
<1
2.
5m
g/
d
b F
o
r 
yo
un
g 
ad
ul
ts 
(18
–2
4 y
ea
rs)
 th
e p
rop
ort
ion
 in
itia
tin
g o
n a
 lo
w
 d
os
e 
pr
e-
20
07
 ex
pa
ns
io
n 
(pe
rio
d 1
–3
) w
as
 1
9.
1%
 an
d 
po
st-
20
07
 ex
pa
ns
io
n 
(pe
rio
d 4
) w
as
 2
4.
2%
, a
 p
er
ce
nt
ag
e-
po
in
t c
ha
ng
e 
of
 5
.1
%
 
(95
% 
CI
: 4
.4–
5.8
)
c D
ep
re
ss
io
n 
di
ag
no
sis
 in
 th
e 
ye
ar
 p
rio
r t
o 
SS
RI
 in
iti
at
io
n 
(IC
D-
9-C
M
 co
de
s: 
29
6.2
x, 
29
6.3
x, 
29
8.0
x, 
30
0.4
x, 
30
9.0
x, 
30
9.1
x, 
31
1.x
x, 
29
3.8
3, 
29
6.9
0, 
an
d 3
09
.28
)
d G
en
er
al
 p
ra
ct
ic
e 
in
cl
ud
ed
 th
e 
se
rv
ic
e 
pr
ov
id
er
s p
ed
ia
tri
cs
, f
am
ily
 p
ra
ct
ic
e,
 a
nd
 g
en
er
al
 p
ra
ct
ic
e
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